LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, announced today that the Company will host an Investor and Ana…
Vision Plan Customer Satisfaction Increases, J.D. Power Finds
COSTA MESA, Calif.–(BUSINESS WIRE)–Overall customer satisfaction among vision plan members has increased in 2019, driven by improved perceptions of value and coverage, J.D. Power finds.
Novel detection method for retinoblastoma
A retinoblastoma is a dangerous cancer often occurring in very young children, under 2, which can cause blindness or the loss of the eye. The tumor is a diffuse, gluey mass spread all over the eye. It also spreads easily. As a result of this, direct bi…
UK adults rank sight as most valuable sense
For adults in the United Kingdom, sight is the most valuable sense, a cross-sectional web-based survey found.Jamie Enoch, MSc, and colleagues collected responses from March 2016 to April 2016 from 250 U.K. adults aged 22 to 80 years. Participants were …
Second Sight to Discuss Third Quarter 2019 Financial Results on November 14, 2019 Conference Call
LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, will releas…
HIMC at Mount Sinai to evaluate therapeutic effects of novel cancer immunotherapy
The Human Immune Monitoring Center at the Icahn School of Medicine at Mount Sinai will apply cutting-edge high-throughput technologies to evaluate the therapeutic effects of Libtayo (cemiplimab-rwlc), a PD-1 antibody blockade developed by biotechnology…